NDA 215887 · Biogen Ma
Qalsody
Tofersen · Intrathecal · Antisense Oligonucleotide
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Apr 25, 2023: To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation
Last checked: Nov 20, 2026Latest source record: Apr 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Apr 25, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
3 Phase 3, 2 recruiting
FAERS reports
567
309 serious, 125 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 23, 2026.
QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). QALSODY is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). ( 1 )
Mechanism: Tofersen is an antisense oligonucleotide that causes degradation of SOD1 mRNA through binding to SOD1 mRNA, which results in a reduction of SOD1 protein synthesis.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 25, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- QALSODY · TOFERSEN 100MG/15ML (6.7MG/ML) · SOLUTION, INTRATHECAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tofersen" as an intervention, any sponsor and status, largest first.
- An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02623699 · 176 participants · Start Jan 20, 2016 · Primary completion Jul 16, 2021
Drug: Tofersen; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; La Jolla, California; San Francisco, California · 40 sites in all
- Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS SymptomsPivotal-lookingActive, not recruiting
BiogenBiogen (BIIB)
NCT04856982 · 158 participants · Start May 17, 2021 · Primary completion Aug 7, 2027
Drug: Tofersen; Placebo · For: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Sites: Scottsdale, Arizona; La Jolla, California; San Francisco, California · 32 sites in all
- Long-Term Evaluation of BIIB067 (Tofersen)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT03070119 · 139 participants · Start Mar 8, 2017 · Primary completion Aug 12, 2024
Drug: Tofersen · For: ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Sites: Phoenix, Arizona; La Jolla, California; San Francisco, California · 30 sites in all
- Tofersen in Non-SOD1 ALSRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT07294144 · 30 participants (planned) · Start Dec 29, 2025 · Primary completion Jan 2027
Drug: Tofersen · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Atlanta, Georgia; Boston, Massachusetts; St Louis, Missouri
- A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)Active, not recruiting
BiogenBiogen (BIIB)
NCT07223723 · 12 participants (planned) · Start Dec 11, 2025 · Primary completion May 26, 2027
Drug: Tofersen · For: Amyotrophic Lateral Sclerosis
Sites: Beijing, China
BiogenBiogen (BIIB)
NCT03764488 · 8 participants · Start Dec 20, 2018 · Primary completion Jun 10, 2021
Drug: Tofersen; 99mTc-MAG3-BIIB067 · For: Healthy Volunteers
Sites: Boston, Massachusetts; New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- amyotrophic lateral sclerosis66
- death57
- headache57
- procedural pain46
- post lumbar puncture syndrome35
- fall27
- csf protein increased26
- back pain23
- fatigue23
- muscular weakness20
- pain in extremity20
- pain19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 57 |
| 2024 | 166 |
| 2025 | 189 |
| 2026 | 155 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Qalsody (Tofersen)
2024 spending
$1.1M
Beneficiaries
11
71 claims
Per beneficiary
$99,927
$990.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $454,058 |
| 2024 | $1,099,192 |
Part B: Qalsody (Tofersen) · HCPCS J1304
2024 spending
$5.8M
Beneficiaries
54
394 claims
Per beneficiary
$108,202
2024 ASP limit $151.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $5,842,933 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Hamad AA, Alkhawaldeh IM, Nashwan AJ, et al. · Neurol Sci 2025 · Systematic Review, Meta-Analysis
- Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller T, Cudkowicz M, Shaw PJ, et al. · N Engl J Med 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.
Miller TM, Cudkowicz ME, Shaw PJ, et al. · JAMA Neurol 2026 · Clinical Trial, Phase III, Multicenter Study
- Safety profile of tofersen in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Tarazona-Santabalbina FJ, Belenguer-Varea A, Borrás-Blasco J, et al. · Neurol Sci 2026 · Systematic Review, Meta-Analysis
- A systematic review and functional in-silico analysis of genes and variants associated with amyotrophic lateral sclerosis.
Arreola-Aldape CA, Moran-Guerrero JA, Pons-Monnier GK, et al. · Front Neurosci 2025 · Systematic Review
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.